Patients randomized and treated in the DB period, N=431

*Abatacept + MTX, n=156
- Discontinuations, n=17 (10.9%)
- Patients completing DB period (Year 1), n=139/156 (89.1%)
- Patients entering LTE, n=132/156 (84.6%)
  - Discontinuations, n=12/132; (9.1%)
    - Withdrawal of consent, n=4 (3.0%)
    - Lack of efficacy, n=3 (2.3%)
    - Death, n=2 (1.5%)
    - Adverse event, n=1 (0.8%)
    - Lost to follow up, n=1 (0.8%)
    - Other, n=1 (0.8%)
  - Ongoing at Year 2, n=120/132 (90.9%)

*Infliximab + MTX, n=165
- Discontinuations, n=24 (14.6%)
- Patients completing DB period (Year 1), n=141/165 (85.5%)
- Patients entering LTE, n=136/165 (82.4%)
  - Discontinuations, n=13/136 (9.6%)
    - Withdrawal of consent, n=3 (2.2%)
    - Lack of efficacy, n=4 (2.9%)
    - Death, n=0
    - Adverse event, n=5 (3.7%)
    - Lost to follow up, n=1 (0.7%)
    - Other, n=0
  - Ongoing at Year 2, n=123/136 (90.4%)

*Placebo + MTX, n=110
- Discontinuations, n=6 (5.5%)
- Patients completing DB period (Year 1), n=104/110 (94.5%)
- Patients entering LTE, n=104/110 (94.5%)
  - Discontinuations, n=3/104 (2.9%)
    - Withdrawal of consent, n=0
    - Lack of efficacy, n=1 (1.0%)
    - Death, n=0
    - Adverse event, n=1 (1.0%)
    - Lost to follow up, n=1 (1.0%)
    - Other, n=0
  - Ongoing at Year 2, n=101/104 (97.1%)

*Represents original randomization groups: patients randomized to placebo and infliximab were switched to abatacept at Month 6 and Year 1, respectively.